Comparing to other solid tumour types, HGSOCs harbours more inactivating mutation in tumour suppressor genes such as p53, NF1, RB1 but rare activating mutations in oncogenes such as KRAS, BRAF, PTEN, HERS, EGFR and KIT.25 The facts that ovarian cancers are often discovered in the late course of disease and this research chose high‐grade ovarian cancers as objects may also contribute to the low immunogenicity detected. This evidence concerns the gene EGFR and ovarian cancer.